CareFirst BlueCross BlueShield (CareFirst), today announced that it has reached a positive coverage decision for the ExoDx® Prostate(IntelliScore) or EPI test – meaning that the test will be covered for CareFirst members beginning in 2018. This coverage decision is based ...
Read More »
World’s First and Only Test Analyzing Genetic Information from Exosomes Via a Simple Urine Collection Requiring No Digital Rectal Exam Potential to Avoid Over One Million Unnecessary Prostate Biopsies Each Year Worldwide Exosome Diagnostics, Inc. announced the launch of its ...
Read More »
from Urology Times by Lisette Hilton – The experimental ExoDx Prostate IntelliScore urine exosome assay (Exosome Diagnostics) outperformed the PSA test for detecting high-grade prostate cancer on biopsy, according to a new study. One prostate cancer expert told Urology Times ...
Read More »
Exosome RNA Exosome RNA Research & Industry News
